{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T02:13:38Z","timestamp":1788401618264,"version":"build-2803163510"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","license":[{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background and aims:<\/jats:title>\n                    <jats:p>Adolescents can have severe\/chronic outcomes from COVID-19. Real-world data on relative vaccine effectiveness between mRNA- and protein-based vaccines are limited, and more data are needed on disease outcomes in this age group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The K-COV-N database, COVID-19 vaccine registry and health insurance claims were retrospectively reviewed to identify adolescents (12- to 18-year-olds) in South Korea who received a homologous primary series of NVX-CoV2373 or BNT162b2 and a heterologous or homologous third vaccine dose. Vaccine recipients were propensity score matched to reduce confounding baseline factors. Adjusted hazard ratios (aHRs) for any medically attended COVID-19 postvaccination (starting 14 days after primary series and 7 days after a third dose) were calculated to assess relative vaccine effectiveness every 30 days through a 180-day risk window.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>From February to December 2022, 3174 and 6253 doses of NVX-CoV2373 and BNT162b2, respectively, were administered to South Korean adolescents. Individuals who received NVX-CoV2373 tended to be older, have a disability, and\/or have a prior SARS-CoV-2 infection. Propensity score matching resulted in 107 individuals in each primary series group and 701 and 1417 individuals in the NVX-CoV2373 and BNT162b2 third-dose groups, respectively. The aHR (95% CI) for NVX-CoV2373 compared with BNT162b2 for medically attended COVID-19 in the 180-day risk window was 0.57 (0.31\u20131.05) for the primary series and 0.68 (0.54\u20130.84) for the third dose.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>These results suggest that NVX-CoV2373 may provide more robust protection against medically attended COVID-19 as a third dose, compared with BNT162b2. While the aHR for the primary series also indicated lower risk with NVX-CoV2373, this difference was not statistically significant.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/inf.0000000000004954","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T22:00:07Z","timestamp":1756332007000},"page":"1134-1140","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Effectiveness of NVX-CoV2373 and BNT162b2 COVID-19 Vaccination in South Korean Adolescents"],"prefix":"10.1097","volume":"44","author":[{"given":"Eunseon","family":"Gwak","sequence":"first","affiliation":[{"name":"Department of Preventive Medicine, Korea University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Ah","family":"Choe","sequence":"additional","affiliation":[{"name":"Department of Preventive Medicine, Korea University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyuwon","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Preventive Medicine, Korea University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erdenetuya","family":"Bolormaa","sequence":"additional","affiliation":[{"name":"Department of Preventive Medicine, Korea University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela H.","family":"Gschwend","sequence":"additional","affiliation":[{"name":"Department of Preventive Medicine, Korea University College of Medicine, Seoul, Republic of Korea"},{"name":"Novavax, Inc., Gaithersburg, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Fix","sequence":"additional","affiliation":[{"name":"Novavax, Inc., Gaithersburg, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muruga","family":"Vadivale","sequence":"additional","affiliation":[{"name":"Novavax, Inc., Gaithersburg, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D.","family":"Rousculp","sequence":"additional","affiliation":[{"name":"Novavax, Inc., Gaithersburg, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young June","family":"Choe","sequence":"additional","affiliation":[{"name":"Department of Preventive Medicine, Korea University College of Medicine, Seoul, Republic of Korea"},{"name":"Department of Pediatrics, Korea University College of Medicine and Korea University Anam Hospital, Seoul, Republic of Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,8,27]]},"reference":[{"key":"R4-20251013","doi-asserted-by":"crossref","first-page":"e239135","DOI":"10.1001\/jamanetworkopen.2023.9135","article-title":"Safety, immunogenicity, and efficacy of the NVX-CoV2373 COVID-19 vaccine in adolescents: a randomized clinical trial.","volume":"6","author":"\u00c1\u00f1ez","year":"2023","journal-title":"JAMA Netw Open"},{"key":"R5-20251013","doi-asserted-by":"crossref","first-page":"106428","DOI":"10.1016\/j.jinf.2025.106428","article-title":"Safety and immunogenicity of omicron protein vaccines in mRNA-vaccinated adolescents: a phase 3, randomised trial.","volume":"90","author":"Bennett","year":"2025","journal-title":"J Infect"},{"key":"R6-20251013","doi-asserted-by":"crossref","first-page":"100984","DOI":"10.1016\/j.lanmic.2024.100984","article-title":"Vaccine efficacy of NVX-CoV2373 against SARS-CoV-2 infection in adolescents in the USA: an ancillary study to a phase 3, observer-blinded, randomised, placebo-controlled trial.","volume":"6","author":"Deming","year":"2025","journal-title":"Lancet Microbe"},{"key":"R7-20251013","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.1016\/j.jinf.2023.01.001","article-title":"Effectiveness of COVID-19 vaccine in children and adolescents with the Omicron variant: a systematic review and meta-analysis.","volume":"86","author":"Li","year":"2023","journal-title":"J Infect"},{"key":"R8-20251013","doi-asserted-by":"crossref","first-page":"e2023062520","DOI":"10.1542\/peds.2023-062520","article-title":"COVID-19 vaccine effectiveness among adolescents.","volume":"153","author":"Poukka","year":"2024","journal-title":"Pediatrics"},{"key":"R9-20251013","doi-asserted-by":"crossref","first-page":"e2222126","DOI":"10.1001\/jamanetworkopen.2022.22126","article-title":"Incidence and relative risk of COVID-19 in adolescents and youth compared with older adults in 19 US states, Fall 2020.","volume":"5","author":"Schneiderman","year":"2022","journal-title":"JAMA Netw Open"},{"key":"R11-20251013","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3947\/ic.2024.0142","article-title":"COVID-19 vaccination recommendations for 2024-2025 in Korea.","volume":"56","author":"Park","year":"2024","journal-title":"Infect Chemother"},{"key":"R12-20251013","doi-asserted-by":"crossref","first-page":"e002391","DOI":"10.1136\/bmjpo-2023-002391","article-title":"Universal versus risk-based strategies for vaccinating children against COVID-19: Japan and Korea.","volume":"8","author":"Choe","year":"2024","journal-title":"BMJ Paediatr Open"},{"key":"R13-20251013","doi-asserted-by":"crossref","first-page":"e2324246","DOI":"10.1001\/jamanetworkopen.2023.24246","article-title":"Incidence and characteristics in children with post\u2013COVID-19 condition in Sweden.","volume":"6","author":"Bygdell","year":"2023","journal-title":"JAMA Netw Open"},{"key":"R14-20251013","doi-asserted-by":"crossref","first-page":"126499","DOI":"10.1016\/j.vaccine.2024.126499","article-title":"Multisystem inflammatory syndrome in children (MIS-C) cases by vaccination status in California.","volume":"43","author":"Le Marchand","year":"2025","journal-title":"Vaccine"},{"key":"R15-20251013","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S2352-4642(22)00028-1","article-title":"Reported cases of multisystem inflammatory syndrome in children aged 12-20 years in the USA who received a COVID-19 vaccine, December, 2020, through August, 2021: a surveillance investigation.","volume":"6","author":"Yousaf","year":"2022","journal-title":"Lancet Child Adolesc Health"},{"key":"R16-20251013","first-page":"738","article-title":"School absenteeism in children and adolescents.","volume":"98","author":"Allen","year":"2018","journal-title":"Am Fam Physician"},{"key":"R17-20251013","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1080\/03054985.2024.2308520","article-title":"School absences, academic achievement, and adolescents\u2019 post-school destinations.","volume":"51","author":"Klein","year":"2024","journal-title":"Oxf Rev Educ"},{"key":"R18-20251013","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/s41390-020-1015-2","article-title":"Coronavirus disease 2019 (COVID-19) in children and\/or adolescents: a meta-analysis.","volume":"89","author":"Mantovani","year":"2021","journal-title":"Pediatr Res"},{"key":"R20-20251013","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S1473-3099(22)00069-X","article-title":"SARS-CoV-2 incidence, transmission, and reinfection in a rural and an urban setting: results of the PHIRST-C cohort study, South Africa, 2020-21.","volume":"22","author":"Cohen","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"R21-20251013","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1097\/INF.0000000000004463","article-title":"Relative effectiveness of the NVX-CoV2373 vaccine compared with the BNT162b2 vaccine in adolescents.","volume":"43","author":"Lee","year":"2024","journal-title":"Pediatr Infect Dis J"},{"key":"R22-20251013","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples.","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"key":"R24-20251013","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s12887-022-03175-8","article-title":"Child transmission of SARS-CoV-2: a systematic review and meta-analysis.","volume":"22","author":"Silverberg","year":"2022","journal-title":"BMC Pediatr"},{"key":"R25-20251013","doi-asserted-by":"crossref","first-page":"e0288557","DOI":"10.1371\/journal.pone.0288557","article-title":"Kinetics of specific anti-SARS-CoV-2 IgM, IgA, and IgG responses during the first 12 months after SARS-CoV-2 infection: a prospective longitudinal study.","volume":"18","author":"Amellal","year":"2023","journal-title":"PLoS One"},{"key":"R26-20251013","doi-asserted-by":"crossref","first-page":"1346749","DOI":"10.3389\/fimmu.2024.1346749","article-title":"Comparison of SARS-CoV-2 spike-specific IgA and IgG in nasal secretions, saliva and serum.","volume":"15","author":"Bladh","year":"2024","journal-title":"Front Immunol"},{"key":"R27-20251013","first-page":"2025.01.21.25320906","article-title":"Detection of anti\u2013SARS-CoV-2 mucosal IgA in clinical saliva samples after a dose of Novavax COVID-19 vaccine.","author":"Zhu","year":"2025","journal-title":"medRxiv"},{"key":"R28-20251013","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jinf.2023.06.007","article-title":"Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): a randomised controlled trial.","volume":"87","author":"Kelly","year":"2023","journal-title":"J Infect"},{"key":"R29-20251013","doi-asserted-by":"crossref","first-page":"e41451","DOI":"10.1371\/journal.pone.0041451","article-title":"Matrix-M\u2122 adjuvant induces local recruitment, activation and maturation of central immune cells in absence of antigen.","volume":"7","author":"Reimer","year":"2012","journal-title":"PLoS One"},{"key":"R30-20251013","doi-asserted-by":"crossref","first-page":"105321","DOI":"10.1016\/j.jcv.2022.105321","article-title":"NVX-CoV2373-induced cellular and humoral immunity towards parental SARS-CoV-2 and VOCs compared to BNT162b2 and mRNA-1273-regimens.","volume":"157","author":"Hielscher","year":"2022","journal-title":"J Clin Virol"},{"key":"R31-20251013","doi-asserted-by":"crossref","first-page":"1081933","DOI":"10.3389\/fimmu.2023.1081933","article-title":"NVX-CoV2373-induced T- and B-cellular immunity in immunosuppressed people with multiple sclerosis that failed to respond to mRNA and viral vector SARS-CoV-2 vaccines.","volume":"14","author":"Mueller-Enz","year":"2023","journal-title":"Front Immunol"},{"key":"R32-20251013","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/s41541-024-00893-1","article-title":"Myocarditis associated with COVID-19 vaccination.","volume":"9","author":"Buoninfante","year":"2024","journal-title":"NPJ Vaccines"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000004954","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:09:51Z","timestamp":1760375391000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000004954"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,27]]},"references-count":26,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000004954","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2025.04.11.25325672","asserted-by":"object"}]},"ISSN":["0891-3668","1532-0987"],"issn-type":[{"value":"0891-3668","type":"print"},{"value":"1532-0987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,27]]}}}